🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congrats to Dr Adeel Khan Adeel Khan MD MPH MS of UT Southwestern Medical Center UTSW Simmons Cancer Center on a fantastic presentation at #ASH2024 on real world outcomes in Teclistsmab given in the community vs academic setting (confirms can be safe and effective at either). #Flatirondatabase

Congrats Dr Ailawadhi on a fantastic presentation at #ASH24 for our CLOVER-WaM study of Iopofosine I 131 in relapsed WM. ORR 83.6%, MRR 58.2%, median 4 prior LOT Cellectar Biosciences UTSW Simmons Cancer Center

Serum free light chains in a racially diverse population including African Americans and populations from South Africa ashpublications.org/blood/article-… #mmsm

#Tandem25 shout-out to the US #MMsm Immunotherapy Consortium for 3 posters tonight! 1️⃣ EMD with teclistamab - paraskeletal disease not as benign as it might seem 2️⃣ teclistamab with dialysis - no issues 3️⃣ post-CAR-T driving restrictions - not evidence based to go to 8 weeks!

#Myeloma Paper of the Day: Comparison of standard-of-care Ide-cel and Cilta-cel in relapsed/refractory myeloma finds Cilta associated w/ higher likelihood of grade ≥3 CRS, SPMs, and delayed neurotox, but better treatment responses, PFS, and OS: pubmed.ncbi.nlm.nih.gov/39965175/. #mmsm

Congrats to #dorishansen Krina Patel Surbhi Sidana, MD and the rest of the US myeloma immunotherapy consortium on this excellent #MMsm work, now out in Journal of Clinical Oncology!

Myeloma Paper of the Day, March 17th, suggested by Robert Z. Orlowski Rahul Banerjee, MD, FACP Larry Anderson,MD,PhD,FACP Gurbakhash Kaur oncodaily.com/science/myelom… #Myeloma #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX #MedNews

We’re excited to welcome Jaehyuk Choi to UTSW as the inaugural Director of the Center for Cellular Therapies & Cancer Immunology at Simmons Cancer Center. This center will focus on treating solid tumors with cellular therapies. Read more about Dr. Choi. bit.ly/43bdgbP

Cilta-cel associated Parkinsonism remains a challenge. Instead of going right to high dose Cy which can be toxic to circulating CAR T cells, we opted to try intrathecal chemotherapy in 5 consecutive cases. 4/5 pts had a response and 3 complete resolution! IT chemo seemed to be

Happy to share our new work out today on Blood Journals Portfolio #Blood where we report CD38 loss as recurrent mechanisms of resistance to anti-CD38 antibody in multiple myeloma. Great collaboration between Memorial Sloan Kettering Cancer Center MSK Department of Medicine U Calgary Heidelberg Myeloma Mayo Clinic #mmsm #wgs

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma | Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

#Myeloma Paper of the Day: Patients w/ >8.7 mos between last exposure to prior BCMA-directed therapy & teclistamab have significantly improved median PFS w/ tec (8.1 mos, 95% CI: 4.6-11.7) vs. pts with <8.7 mos (2.5 ms, 95% CI: 1.1-5.7), p=0.001: pubmed.ncbi.nlm.nih.gov/40562770/. #mmsm

Great Blood Cancer Journal RW data from US #MMsm consortium, led by Danai Dima Leyla Shune MD et al! BCMA bsAbs can work in BCMA-exposed. While we await better predictive tools, time & type of prior therapy matters: - ⬆️ PFS if > 9 months since prior BCMA - ⬇️ PFS if prior BCMA was bsAb

2/ heard through Mazyar Shadman, MD MPH Link to company announcement: news.bms.com/news/corporate…

Big News for CAR T cell delivery to patients and monitoring: FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies #FDA #Tcellrx #immunotherapy fda.gov/vaccines-blood…

Blood Advances 4/ UPDATE - FDA announcement now out, and sorry I spoke too soon! REMS are now eliminated entirely across products: this is excellent news for patients. Our CAR-T programs have the expertise needed to personalize safety monitoring. Thanks to advocacy by ASTCT & many others 🙏

Fantastic Internal Med Grand Rounds today by Aimaz Afrough on T-Cell therapies in Myeloma. Especially CarT (older sister, takes longer to get ready, elegant & custom made) vs BsAbs (younger bro shows up immediately, figures it out on the way but constant babysitting w/IVIG &

FDA Eliminates REMS for Chimeric Antigen Receptor (CAR) T cell Immunotherapies. Pts now only need to remain close to CAR T facility for 2 weeks (no longer 4 weeks) and avoid driving for 2 weeks (no longer 8 weeks) following CAR T. Huge access improvement! fda.gov/vaccines-blood…

Study now open UT Southwestern Medical Center. Patients newly diagnosed with MM in the Dallas area can receive personalized response-adapted treatment with the wonderful Larry Anderson,MD,PhD,FACP Aimaz Afrough HealthTree Foundation #MMSM UTSW Simmons Cancer Center